With 65% revenue growth, Castle Biosciences (CSTL) will be a name to be followed carefully after the IPO. The company sells a product that does not seem to need a lot of marketing efforts. Additionally, several academic journals featured the company's technology, and Medicare is responsible for 53% of the company's amount of revenue. With that, the shares are being sold at 5.4x sales, which is not expensive. However, savvy individuals will be looking to buy at 3x-3.5x revenue.
Source: Prospectus
Source: Prospectus
Business
Founded in 2007, Castle Biosciences, Inc. offers actionable genomic information that